8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 7, 2026·SEC
Material company update
Mar 5, 2026·SEC
MetLife, Inc.(MET)Earnings, Financials & Key Ratios
MET•NYSE•Insurance & Managed Care
17.8× P/E·Price updated Jun 19, 2026
SectorFinancial ServicesIndustryLife InsuranceSub-IndustryDiversified global life and asset managers
AboutMetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; and pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was founded in 1863 and is headquartered in New York, New York.Show more
- Revenue$77.08B+10.2%
- Combined Ratio93.95%+2.2%
- Net Income$3.38B-23.7%
- Return on Equity11.93%-21.9%
- Medical Cost Ratio63.64%-12.6%
- Operating Margin6.05%-24.8%
- Net Margin4.38%-30.7%
- ROA0.47%-26.8%
- Equity / Assets3.88%-5.1%
MET Key Insights
MetLife, Inc. (MET) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Profitable underwriting: 94.0% combined ratio
- ✓Strong Piotroski F-Score: 8/9
- ✓13 consecutive years of dividend growth
- ✓Healthy dividend yield of 2.7%
- ✓Share count reduced 6.5% through buybacks
- ✓Trading near 52-week high
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MET posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MET Price & Volume
MetLife, Inc. (MET) stock price & volume — 10-year historical chart
Loading chart...
MET Growth Metrics
MetLife, Inc. (MET) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years2.31%
5 Years2.57%
3 Years4.29%
TTM6.14%
Profit CAGR
10 Years-4.53%
5 Years-8.97%
3 Years-13.85%
TTM-19.65%
EPS CAGR
10 Years0.49%
5 Years-3.31%
3 Years-8.67%
TTM-16.1%
Return on Capital
10 Years0.96%
5 Years1.19%
3 Years0.96%
Last Year1.05%
MET Recent Earnings
MetLife, Inc. (MET) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 1/12 qtrs (8%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$2.42+6.6%
$2.27
Rev
$19.1B-2.1%
$19.5B
Q1 2026
Feb 4, 2026Metric
Actual
Est
EPS
$2.58+10.3%
$2.34
Rev
$23.8B-12.5%
$27.2B
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$2.34+1.3%
$2.31
Rev
$16.9B-9.4%
$18.6B
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$2.02-6.0%
$2.15
Rev
$17.3B-6.4%
$18.5B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $2.42vs $2.27+6.6% | $19.1Bvs $19.5B-2.1% |
| Q1 2026 | Feb 4, 2026 | $2.58vs $2.34+10.3% | $23.8Bvs $27.2B-12.5% |
| Q4 2025 | Nov 5, 2025 | $2.34vs $2.31+1.3% | $16.9Bvs $18.6B-9.4% |
| Q3 2025 | Aug 6, 2025 | $2.02vs $2.15-6.0% | $17.3Bvs $18.5B-6.4% |
Based on last 12 quarters of dataView full earnings history →
MET Peer Comparison
MetLife, Inc. (MET) competitors in Diversified global life and asset managers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRU | 37.05B | 106.53 | 10.42 | -14.01% | 5.62% | 10.26% | 0.65 | |
 LNC | 7.11B | 37.17 | 6.36 | 1.24% | 9.14% | 16.79% | 0.59 | |
 UNM | 14.53B | 89.98 | 21.02 | 2.07% | 5.87% | 7.07% | 0.35 | |
 PFG | 23.74B | 109.57 | 20.87 | -3.11% | 7.58% | 9.89% | 0.34 | |
 EQH | 12.75B | 45.29 | -9.38 | -6.21% | -12.55% | -49.32% | 3.67 | |
 GNW | 3.45B | 8.95 | 16.57 | -10.86% | 3.62% | 2.54% | 0.15 | |
 AFL | 59.49B | 115.47 | 16.91 | -8.84% | 21% | 13.05% | 0.29 | |
 GL | 13.4B | 170.76 | 12.15 | 3.82% | 19.36% | 20.64% | 0.44 |
Compare MET vs Peers
MetLife, Inc. (MET) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MET Income Statement
MetLife, Inc. (MET) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 62.31B | 67.94B | 69.62B | 67.89B | 63.37B | 67.97B | 67.71B | 69.94B | 77.08B | 76.94B |
Revenue Growth % | 2.94% | 9.04% | 2.47% | -2.49% | -6.66% | 7.26% | -0.38% | 3.29% | 10.22% | 6.14% |
Medical Costs & Claims | 48.85B | 52.04B | 53.43B | 52.42B | 46.53B | 49.03B | 50.42B | 50.94B | 49.06B | 55.09B |
Medical Cost Ratio % | 78.39% | 76.6% | 76.75% | 77.21% | 73.43% | 72.14% | 74.47% | 72.83% | 63.64% | 71.6% |
Gross Profit | 13.46B▲ 0% | 15.9B▲ 18.1% | 16.19B▲ 1.8% | 15.47B▼ 4.4% | 16.84B▲ 8.8% | 18.94B▲ 12.5% | 17.29B▼ 8.7% | 19B▲ 9.9% | 28.02B▲ 47.5% | 21.85B▲ 0% |
Gross Margin % | 21.61% | 23.4% | 23.25% | 22.79% | 26.57% | 27.86% | 25.53% | 27.17% | 36.36% | 28.4% |
Gross Profit Growth % | -3.53% | 18.11% | 1.82% | -4.45% | 8.83% | 12.48% | -8.7% | 9.89% | 47.5% | - |
Operating Expenses | 9.93B | 9.59B | 9.39B | 8.54B | 8.32B | 12.57B | 15.13B | 13.38B | 23.36B | 17.04B |
OpEx / Revenue % | 15.93% | 14.12% | 13.49% | 12.58% | 13.13% | 18.5% | 22.34% | 19.13% | 30.31% | 22.14% |
Depreciation & Amortization | 795M | 628M | 630M | 619M | 694M | 673M | 718M | 714M | 0 | 0 |
Combined Ratio % | 94.32% | 90.72% | 90.24% | 89.8% | 86.56% | 90.64% | 96.81% | 91.96% | 93.95% | 93.74% |
Operating Income | 3.54B▲ 0% | 6.31B▲ 78.4% | 6.79B▲ 7.7% | 6.93B▲ 1.9% | 8.52B▲ 23.0% | 6.36B▼ 25.3% | 2.16B▼ 66.0% | 5.62B▲ 160.0% | 4.66B▼ 17.1% | 4.81B▲ 0% |
Operating Margin % | 5.68% | 9.28% | 9.76% | 10.2% | 13.44% | 9.36% | 3.19% | 8.04% | 6.05% | 6.26% |
Operating Income Growth % | -17.4% | 78.37% | 7.74% | 1.94% | 22.97% | -25.29% | -66.03% | 160.04% | -17.09% | - |
EBITDA | 4.33B | 6.93B | 7.42B | 7.55B | 9.21B | 7.04B | 2.88B | 6.34B | 5.72B | 5.88B |
EBITDA Margin % | 6.95% | 10.21% | 10.67% | 11.12% | 14.54% | 10.35% | 4.25% | 9.06% | 7.42% | 7.64% |
Interest Expense | 1.13B | 1.12B | 955M | 913M | 920M | 938M | 1.04B | 1.04B | 1.06B | 1.07B |
Non-Operating Income | -1.13B | -1.12B | -955M | -913M | -920M | -938M | -1.04B | -1.04B | -1.06B | -1.07B |
Pretax Income | 3.54B▲ 0% | 6.31B▲ 78.4% | 6.79B▲ 7.7% | 6.93B▲ 1.9% | 8.52B▲ 23.0% | 6.36B▼ 25.3% | 2.16B▼ 66.0% | 5.62B▲ 160.0% | 4.66B▼ 17.1% | 4.81B▲ 0% |
Pretax Margin % | 5.68% | 9.28% | 9.76% | 10.2% | 13.44% | 9.36% | 3.19% | 8.04% | 6.05% | 6.26% |
Income Tax | -1.47B | 1.18B | 886M | 1.51B | 1.64B | 1.06B | 560M | 1.18B | 1.26B | 1.2B |
Effective Tax Rate % | -41.57% | 18.69% | 13.04% | 21.78% | 19.28% | 16.69% | 25.9% | 20.95% | 26.99% | 24.91% |
Net Income | 4.01B▲ 0% | 5.12B▲ 27.8% | 5.9B▲ 15.1% | 5.41B▼ 8.3% | 6.86B▲ 26.8% | 5.28B▼ 22.9% | 1.58B▼ 70.1% | 4.43B▲ 180.5% | 3.38B▼ 23.7% | 3.62B▲ 0% |
Net Margin % | 6.44% | 7.54% | 8.47% | 7.96% | 10.82% | 7.77% | 2.33% | 6.33% | 4.38% | 4.7% |
Net Income Growth % | 371.76% | 27.76% | 15.15% | -8.34% | 26.78% | -22.92% | -70.14% | 180.48% | -23.66% | -19.65% |
EPS (Diluted) | 3.74▲ 0% | 4.91▲ 31.3% | 6.06▲ 23.4% | 5.68▼ 6.3% | 7.65▲ 34.7% | 6.30▼ 17.6% | 1.81▼ 71.3% | 5.94▲ 228.2% | 4.80▼ 19.2% | 5.52▲ 0% |
EPS Growth % | 458.21% | 31.28% | 23.42% | -6.27% | 34.68% | -17.65% | -71.27% | 228.18% | -19.19% | -16.1% |
EPS (Basic) | 3.74 | 4.95 | 6.10 | 5.72 | 7.70 | 6.35 | 1.82 | 5.98 | 4.80 | - |
Diluted Shares Outstanding | 1.04B | 1.01B | 944.4M | 913.2M | 869.4M | 808.9M | 762.43M | 711.1M | 664.96M | 655.7M |
MET Balance Sheet
MetLife, Inc. (MET) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Assets | 719.89B | 687.54B | 740.46B | 795.15B | 759.71B | 663.07B | 687.58B | 677.46B | 745.17B | 743.21B |
Asset Growth % | -19.9% | -4.49% | 7.7% | 7.38% | -4.46% | -12.72% | 3.7% | -1.47% | 9.99% | 24.02% |
Total Investment Assets | 444.07B | 436.21B | 473.8B | 508.52B | 494.82B | 427.95B | 440.38B | 435.38B | 466.11B | 4M |
Long-Term Investments | 338.77B | 322.87B | 353.83B | 382.58B | 147.37B | 134.83B | 144.19B | 346.67B | 362.81B | 1.69T |
Short-Term Investments | 313.8B | 302.2B | 331.67B | 358.71B | 347.45B | 293.13B | 296.19B | 88.71B | 103.31B | 316.11B |
Total Current Assets | 0 | 0 | 0 | 0 | 388.01B | 335.49B | 350.62B | 143.04B | 179.59B | 73.02B |
Cash & Equivalents | 12.7B | 15.82B | 16.6B | 19.8B | 20.05B | 20.2B | 20.64B | 20.07B | 22.03B | 22.69B |
Receivables | 18.42B | 19.64B | 20.44B | 17.87B | 20.52B | 22.17B | 33.78B | 34.26B | 54.25B | 186.1B |
Other Current Assets | -344.93B | -337.67B | -368.71B | -396.38B | 0 | 0 | 0 | 0 | 0 | -316.11B |
Goodwill & Intangibles | 9.59B | 9.42B | 9.31B | 10.11B | 25.6B | 28.95B | 29.39B | 28.53B | 30.72B | 100.69B |
Goodwill | 9.59B | 9.42B | 9.31B | 10.11B | 9.54B | 9.3B | 9.24B | 8.9B | 9.61B | 9.56B |
Intangible Assets | 0 | 0 | 0 | 0 | 16.06B | 19.65B | 20.15B | 19.63B | 21.11B | 0 |
PP&E (Net) | 0 | 0 | 0 | 0 | 0 | 1.93B | 1.99B | 1.85B | 1.7B | 0 |
Other Assets | -348.36B | -332.29B | -363.14B | -392.69B | 198.54B | 159.44B | 158.79B | 154.38B | 167.77B | 39.83B |
Total Liabilities | 661.02B | 634.58B | 674.08B | 720.33B | 691.96B | 632.95B | 657.33B | 649.75B | 716.25B | 715.41B |
Total Debt | 19.31B | 16.24B | 16.85B | 18.15B | 17.43B | 17.98B | 18.83B | 18.71B | 20.18B | 20.29B |
Net Debt | 6.61B | 423M | 253M | -1.65B | -2.62B | -2.21B | -1.81B | -1.35B | -1.85B | -2.4B |
Long-Term Debt | 18.83B | 15.98B | 16.62B | 17.76B | 17.09B | 17.75B | 18.68B | 18.24B | 18.62B | 19.89B |
Short-Term Debt | 477M | 268M | 235M | 393M | 341M | 175M | 119M | 465M | 1.56B | 404M |
Total Current Liabilities | 0 | 0 | 0 | 0 | 263.18B | 251.08B | 257.57B | 258.07B | 276.14B | 859M |
Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | -1.47B | -1.39B | -1.28B | -1.11B | 230.92B | 229.97B | 239.93B | 240.48B | 257.46B | 455M |
Deferred Taxes | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1.92B |
Other Liabilities | -25.6B | -21.39B | -25.71B | -28.76B | 402B | 363.11B | 380.12B | 373.3B | 420.95B | 695.14B |
Total Equity | 58.87B▲ 0% | 52.96B▼ 10.0% | 66.38B▲ 25.3% | 74.82B▲ 12.7% | 67.75B▼ 9.4% | 30.13B▼ 55.5% | 30.25B▲ 0.4% | 27.7B▼ 8.4% | 28.92B▲ 4.4% | 27.8B▲ 0% |
Equity Growth % | -13.05% | -10.04% | 25.35% | 12.71% | -9.45% | -55.53% | 0.42% | -8.43% | 4.4% | -0.36% |
Shareholders Equity | 58.68B | 52.74B | 66.14B | 74.56B | 67.48B | 29.88B | 30.02B | 27.45B | 28.4B | 27.32B |
Minority Interest | 194M | 217M | 238M | 259M | 267M | 244M | 238M | 258M | 523M | 477M |
Retained Earnings | 26.53B | 28.93B | 33.08B | 36.49B | 41.2B | 40.33B | 40.15B | 42.63B | 44.29B | 45.06B |
Common Stock | 12M | 12M | 12M | 12M | 12M | 12M | 12M | 12M | 12M | 12M |
Accumulated OCI | 7.43B | 1.72B | 13.05B | 18.07B | 10.92B | -22.62B | -19.24B | -21.19B | -18.08B | -19.23B |
Return on Equity (ROE) | 6.34% | 9.16% | 9.89% | 7.66% | 9.62% | 10.8% | 5.23% | 15.27% | 11.93% | 12.72% |
Return on Assets (ROA) | 0.5% | 0.73% | 0.83% | 0.7% | 0.88% | 0.74% | 0.23% | 0.65% | 0.47% | 0.5% |
Equity / Assets | 8.18% | 7.7% | 8.96% | 9.41% | 8.92% | 4.54% | 4.4% | 4.09% | 3.88% | 3.74% |
Debt / Equity | 0.33x | 0.31x | 0.25x | 0.24x | 0.26x | 0.60x | 0.62x | 0.68x | 0.70x | 0.73x |
Book Value per Share | 56.41 | 52.23 | 70.29 | 81.93 | 77.93 | 37.24 | 39.68 | 38.96 | 43.49 | 42.40 |
Tangible BV per Share | 47.22 | 42.94 | 60.43 | 70.86 | 48.49 | 1.45 | 1.14 | -1.16 | -2.71 | 27.81 |
MET Cash Flow Statement
MetLife, Inc. (MET) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 12.72B | 9.53B | 13.93B | 11.51B | 12.83B | 11.37B | 14.26B | 15.12B | 18.11B | 16.53B |
Operating CF Growth % | -13.26% | -25.1% | 46.18% | -17.36% | 11.46% | -11.34% | 25.38% | 6% | 19.77% | -31.02% |
Operating CF / Revenue % | 20.41% | 14.02% | 20% | 16.95% | 20.24% | 16.73% | 21.06% | 21.61% | 23.49% | 21.48% |
Net Income | 5B | 5.12B | 5.9B | 5.41B | 6.55B | 5.28B | 1.58B | 4.43B | 3.38B | 3.62B |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 753M | 0 |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.68B | -1.59B | 462M | 1.38B | 3.64B | 4.19B | 10.5B | 8.84B | 7.14B | 6.91B |
Working Capital Changes | 6.04B | 5.99B | 7.56B | 4.72B | 2.63B | 1.9B | 2.18B | 1.85B | 6.84B | 6B |
Cash from Investing | -16.88B | -5.63B | -17.59B | -18.57B | -11.19B | -2.62B | -10.25B | -11.49B | -15.61B | -17.74B |
Capital Expenditures | 0 | 0 | 0 | 0 | 4.36B | 0 | -1.17B | 0 | 0 | 0 |
Acquisitions | -1.28B | 0 | -1.08B | -1.68B | 3.27B | -709M | -755M | -358M | -738M | -1.23B |
Purchase of Investments | -115.47B | -108.16B | -91.79B | -93.58B | -109.32B | -104.64B | -84.27B | -82.14B | -105.69B | -109.98B |
Sale/Maturity of Investments | 101.52B | 110.13B | 80.01B | 79.06B | 110.79B | 108.43B | 76.1B | 69.94B | 92.87B | 93.72B |
Other Investing | -1.65B | -7.61B | -4.73B | -2.36B | -20.29B | -5.7B | -143M | 1.07B | -2.04B | -251M |
Cash from Financing | -906M | -2.8B | 4.57B | 10.73B | -1.38B | -9.95B | -2.94B | -3.13B | 163M | 3.5B |
Dividends Paid | -1.82B | -1.82B | -1.82B | -1.86B | -1.84B | -1.78B | -1.76B | -1.73B | -1.7B | -1.68B |
Share Repurchases | -2.93B | -3.99B | -2.29B | -2.15B | -4.8B | -3.33B | -3.1B | -3.21B | -3.88B | -2.23B |
Stock Issued | 0 | 1.27B | 0 | 1.96B | 0 | 0 | 0 | 0 | 0 | 0 |
Debt Issuance (Net) | -1000K | -1000K | 1000K | 1000K | -1000K | 1000K | 1000K | -1000K | -1000K | 0 |
Other Financing | 4.21B | 3.64B | 8.27B | 11.9B | 5.9B | -5.72B | 1.05B | 2.79B | 6.32B | 7.69B |
Net Change in Cash | 50M▲ 0% | 3.12B▲ 6140.0% | 777M▼ 75.1% | 3.2B▲ 311.5% | 252M▼ 92.1% | 148M▼ 41.3% | 444M▲ 200.0% | -571M▼ 228.6% | 1.96B▲ 444.0% | 1.36B▲ 0% |
Exchange Rate Effect | 5.11B | 2.03B | -130M | -471M | -13M | 1.34B | -630M | -1.06B | -697M | -931M |
Cash at Beginning | 12.65B | 12.7B | 15.82B | 16.6B | 19.8B | 20.05B | 20.2B | 20.64B | 20.07B | 22.03B |
Cash at End | 12.7B | 15.82B | 16.6B | 19.8B | 20.05B | 20.2B | 20.64B | 20.07B | 22.03B | 22.69B |
Free Cash Flow | 12.72B▲ 0% | 9.53B▼ 25.1% | 13.93B▲ 46.2% | 11.51B▼ 17.4% | 12.83B▲ 11.5% | 11.37B▼ 11.3% | 14.26B▲ 25.4% | 15.12B▲ 6.0% | 18.11B▲ 19.8% | 16.53B▲ 0% |
FCF Growth % | -13.26% | -25.1% | 46.18% | -17.36% | 11.46% | -11.34% | 25.38% | 6% | 19.77% | -3.05% |
FCF Margin % | 20.41% | 14.02% | 20% | 16.95% | 20.24% | 16.73% | 21.06% | 21.61% | 23.49% | 21.48% |
FCF per Share | 12.19 | 9.4 | 14.74 | 12.6 | 14.75 | 14.06 | 18.7 | 21.26 | 27.23 | 25.21 |
MET Key Ratios
MetLife, Inc. (MET) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Combined Ratio | 94.32% | 90.72% | 90.24% | 89.8% | 86.56% | 90.64% | 96.81% | 91.96% | 93.95% | 93.74% |
Medical Cost Ratio | 78.39% | 76.6% | 76.75% | 77.21% | 73.43% | 72.14% | 74.47% | 72.83% | 63.64% | 71.6% |
Return on Equity (ROE) | 6.34% | 9.16% | 9.89% | 7.66% | 9.62% | 10.8% | 5.23% | 15.27% | 11.93% | 12.72% |
Return on Assets (ROA) | 0.5% | 0.73% | 0.83% | 0.7% | 0.88% | 0.74% | 0.23% | 0.65% | 0.47% | 0.5% |
Equity / Assets | 8.18% | 7.7% | 8.96% | 9.41% | 8.92% | 4.54% | 4.4% | 4.09% | 3.88% | 3.74% |
Book Value / Share | 56.41 | 52.23 | 70.29 | 81.93 | 77.93 | 37.24 | 39.68 | 38.96 | 43.49 | 42.4 |
Debt / Equity | 0.33x | 0.31x | 0.25x | 0.24x | 0.26x | 0.60x | 0.62x | 0.68x | 0.70x | 0.73x |
Revenue Growth | 2.94% | 9.04% | 2.47% | -2.49% | -6.66% | 7.26% | -0.38% | 3.29% | 10.22% | 6.14% |
Related:MET Dividend History·MET Revenue History·MET Price History·MET P/E History·MET Financial Ratios·MET Institutional Holders
MET SEC Filings & Documents
MetLife, Inc. (MET) SEC filings — annual & quarterly reports (10-K, 10-Q)
MET Frequently Asked Questions
MetLife, Inc. (MET) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MetLife, Inc. (MET) grew revenue by 10.2% over the past year. This is steady growth.
Yes, MetLife, Inc. (MET) is profitable, generating $3.62B in net income for fiscal year 2025 (4.4% net margin).
Dividend & Returns
Yes, MetLife, Inc. (MET) pays a dividend with a yield of 2.65%. This makes it attractive for income-focused investors.
MetLife, Inc. (MET) has a return on equity (ROE) of 11.9%. This is reasonable for most industries.
Industry Metrics
MetLife, Inc. (MET) has a combined ratio of 94.0%. A ratio below 100% indicates underwriting profitability.